Announcement: Genomics of Drug Sensitivity in Cancer (includes BRCA1/2 in charts)

Announcements for the Genomics of Drug Sensitivity Website
Subject:  Genomics of Drug Sensitivity in Cancer
 
Genomics of Drug Sensitivity in Cancer v1 release
 
We have launched a new website to present genomic markers of sensitivity to
anti-cancer compounds screened across our >1000 cancer cell line resource.
 
New website 
 
The website (http://www.cancerRxgene.org) has enhanced user interfaces
making it simple to access our data and analyses. All of our genetic and
drug sensitivity data, including results from future screening, are freely
available and can be downloaded. The website will be regularly updated as
new data becomes available.
 
Drug sensitivity data
 
We have released sensitivity data for 130 anti-cancer drugs screened across
a large subset of our cell line resource.  Drug sensitivity data for more
than 600 cell lines have been correlated with extensive genetic data to
identify genomic events associated with sensitivity and resistance. This is
the largest publicly available dataset of its type, representing >48,000
drug-cell line combinations, and provides a comprehensive view of the
genomics of drug sensitivity in cancer.
 
Cancer cell line resource
 
Our >1000 cell line resource represents the spectrum of common and rare
types of adult and childhood cancers of epithelial, mesenchymal and
haematopoietic origin. Cell lines have been subjected to sequencing of the
full coding exons of 64 commonly mutated cancer genes, genome-wide analysis
of copy number gain and loss using Affymetrix SNP6.0 microarrays, and
expression profiling of 14,500 genes using Affymetrix HT-U133A microarrays.
The presence of seven commonly rearranged cancer genes and of microsatellite
instability (MSI) has also been investigated.  Genetic data for the cell
lines are available through our website and the Cancer Genome Project
webpages. The cell lines have been submitted for whole-exome sequencing and
this data will soon be available.
 
Integration with COSMIC
 
Our analyses have been integrated with the Catalogue of Somatic Mutations in
Cancer (COSMIC) database providing a comprehensive resource linking somatic
mutations and other information related to cancer with drug sensitivity
information.
 
Data for the following drugs are included in this release:
 
681640, 17-AAG, A-443654, A-769662, A-770041, ABT-263, ABT-888, AICAR, AKT
inhibitor VIII, AMG-706, AP-24534, AS601245, ATRA, AUY922, Axitinib, AZ628,
AZD-0530, AZD-2281, AZD-6244, AZD-6482, AZD-7762, AZD-8055, BAY613606,
Bexarotene, BI-2536, BI-D1870, BIBW2992, Bicalutamide, BIRB 0796, Bleomycin,
BMS-509744, BMS-536924, BMS-754807, Bortezomib, Bosutinib, Bryostatin 1,
BX-795, Camptothecin, CEP-701, CGP-082996, CGP-60474, CHIR-99021, CI-1040,
Cisplatin, CMK, Cyclopamine, Cytarabine, Dasatinib, DMOG, Docetaxel,
Doxorubicin, Elesclomol, Embelin, Epothilone B, Erlotinib, Etoposide, FH535,
FTI-277, GDC-0449, GDC0941, Gefitinib, Gemcitabine, GNF-2, GSK-650394,
GSK269962A, GW 441756, GW843682X, Imatinib, IPA-3, JNK Inhibitor VIII,
JNK-9L, JW-7-52-1, KIN001-135, KU-55933, Lapatinib, Lenalidomide, LFM-A13,
Metformin, Methotrexate, MG-132, Midostaurin, Mitomycin C, MK-2206, MS-275,
Nilotinib, NSC-87877, NU-7441, Nutlin-3a, NVP-BEZ235, NVP-TAE684, Obatoclax
Mesylate, OSI-906, PAC-1, Paclitaxel, Parthenolide, Pazopanib, PD-0325901,
PD-0332991, PD-173074, PF-02341066, PF-562271, PHA-665752, PLX4720,
Pyrimethamine, QS11, Rapamycin, RDEA119, RO-3306, Roscovitine,
S-Trityl-L-cysteine, Salubrinal, SB216763, SB590885, Shikonin, SL 0101-1,
Sorafenib, Sunitinib, Temsirolimus, Thapsigargin, Tipifarnib, Vinblastine,
Vinorelbine, Vorinostat, VX-680, VX-702, WH-4-023, WZ-1-84, XMD8-85,
Z-LLNle-CHO, ZM-447439
 
 
Genomics of Drug Sensitivity in Cancer Team - cancerrxgene@sanger.ac.uk
 
http://www.cancerRxgene.org/